Home

Portage Biotech Inc. - Common Stock (PRTG)

4.5600
0.00 (0.00%)

Portage Biotech Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer

The company is dedicated to advancing its proprietary drug candidates through various stages of clinical development, aiming to address unmet medical needs in oncology. By leveraging its scientific expertise and strategic partnerships, Portage is engaged in researching and developing novel immunotherapies and personalized medicine approaches that aim to improve patient outcomes and enhance the efficacy of existing cancer treatments.

SummaryNewsPress ReleasesChartHistoricalFAQ
“Stocks Under $1 Gaining Momentum: WBUY, KAVL, OMEX, PRTG, RJDG – Driving Innovation, Market Trends, and Growth Potential”
Stocks priced under $1 provide an affordable entry for investors aiming for high potential returns. These five emerging companies show strong growth potential, and with market trends favoring undervalued sectors, they are worth considering now.
Via AB Newswire · September 18, 2024
Portage Biotech CEO Interview Explains Why His Company Can Be Poised To Break Higher In 2H 2021 (NASDAQ: PRTG)
A bullish interview by Portage Biotech (NasdaqCM: PRTG) CEO Ian Walters sets the stage for a return trip back to its YTD highs of $44.98, representing a more than 100% gain from current levels. In fact, everything he said supports the narrative that its current share price is far less indicative of what's happening in the clinic. In fact, with multiple shots on goal, its current share price hardly represents PRTG's industry experience, leadership, and clinical pipeline at all. The excellent news is that with near-term catalysts expected, its valuation gap should close.
Via AB Newswire · July 19, 2021
Portage Biotech Added to Russell 2000(R) Index
Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQPRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology...
Via Newsfile · June 29, 2021
Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares
Westport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (NASDAQPRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology...
Via Newsfile · June 24, 2021
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
Westport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (NASDAQPRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology...
Via Newsfile · June 23, 2021
Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting
- Data from the IT-01 trial demonstrate the safety of INT230-6...
Via Newsfile · June 2, 2021
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange
Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc., (NASDAQPRTG) (CSE: PBT.U) ("Portage" or the "Company") a...
Via Newsfile · April 16, 2021
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
- Novel platform allows co-targeting of iNKT cells and tumor antigens...
Via Newsfile · April 8, 2021